Brain Res

1. KENTROS M, Follett J, Subrahmanian N, Chairmandurai A, et al
   Regulation of LRRK2 activity by metabolic stress and heavy metal exposure.
   Brain Res. 2025;1863:149785.
   

   >> Share

   
   

   
   Exp Neurol

2. WU X, Hui Y, Wang L, Qiao H, et al
   Long-term intermittent theta burst stimulation alleviates Parkinson's disease-related cognitive impairment by modulating GluN2B in the dorsal hippocampus.
   Exp Neurol. 2025;394:115439.
   

   >> Share

   
   
3. MIN X, Du Z, Wei J, Yuan Z, et al
   Corrigendum to "Pyridoxal Phosphate inhibits alpha-synuclein-induced ferroptosis by activating GOT1 to enhance the methionine salvage pathway in Parkinson's Disease" [Experimental Neurology (2025) 115411].
   Exp Neurol. 2025 Aug 20:115429. doi: 10.1016/j.expneurol.2025.115429.
   

   >> Share

   
   

   
   J Clin Psychopharmacol

4. PIRES AC, Faria I, Bajouco M, Mota D, et al
   Clozapine-Resistant Schizophrenia and Wolff-Parkinson-White Syndrome: A Case Report.
   J Clin Psychopharmacol. 2025 Aug 22. doi: 10.1097/JCP.0000000000002055.
   

   >> Share

   
   

   
   J Neural Transm (Vienna)

5. MULLER T, Ohm G, Eilert K, Haas T, et al
   Olfaction function improves in a specialised unit for Parkinson's disease.
   J Neural Transm (Vienna). 2025 Aug 21. doi: 10.1007/s00702-025-02987.
   

   >> Share

   
   
6. RUKAVINA K, Mulholland N, Corcoran B, Skoric MK, et al
   Early parkinson's disease: levodopa requirements are associated with the striatal DaT-uptake.
   J Neural Transm (Vienna). 2025 Aug 16. doi: 10.1007/s00702-025-02999.
   

   >> Share

   
   

   
   Mov Disord

7. KERSEBAUM D, Lassen J, Forstenpointner J, Sendel M, et al
   Electrophysiological Evidence for Impaired Central Pain Modulation in Parkinson's Disease.
   Mov Disord. 2025 Aug 23. doi: 10.1002/mds.70004.
   

   >> Share

   
   
8. LOO RTJ, Pavelka L, Mangone G, Khoury F, et al
   Interpretable Machine Learning for Cross-Cohort Prediction of Motor Fluctuations in Parkinson's Disease.
   Mov Disord. 2025;40:1604-1617.
   

   >> Share

   
   
9. YIN KF, Gu XJ, Yu JM, Su WM, et al
   Epigenetic Mediating Mechanisms in Parkinson's Disease: The Impact of Educational Attainment on SETD1A Expression.
   Mov Disord. 2025 Aug 19. doi: 10.1002/mds.70010.
   

   >> Share

   
   
10. VARGAS GONZALEZ E, Yang Z, Dodet P, Leu-Semenescu S, et al
    Rapid Eye Movements (REMs) during Non-REM Sleep as a Marker of Alpha-Synucleinopathies.
    Mov Disord. 2025;40:1595-1603.
    

    >> Share

    
    
11. BRINKERHOFF S, Nakhmani A, Varghese A, Gordon C, et al
    Paired Deep Brain Stimuli Elicit Short-Term Facilitation in Globus Pallidus Interna and Subthalamic Nucleus.
    Mov Disord. 2025;40:1636-1647.
    

    >> Share

    
    

    
    Nat Med

12. IMAM F, Saloner R, Vogel JW, Krish V, et al
    The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging.
    Nat Med. 2025;31:2556-2566.
    

    >> Share

    
    
13. SHVETCOV A, Johnson ECB, Winchester LM, Walker KA, et al
    APOE epsilon4 carriers share immune-related proteomic changes across neurodegenerative diseases.
    Nat Med. 2025;31:2590-2601.
    

    >> Share

    
    

    
    Neurobiol Dis

14. GRILLO P, Di Martino D, Calculli A, De Icco R, et al
    Physical exercise modulates plasma irisin levels in endurance athletes: Implications for Parkinson's disease.
    Neurobiol Dis. 2025 Aug 23:107065. doi: 10.1016/j.nbd.2025.107065.
    

    >> Share

    
    

    
    Neurology

15. ZHANG X, Wang J, Dove A, Yu T, et al
    Metabolic Syndrome and Incidence of Parkinson Disease: A Community-Based Longitudinal Study and Meta-Analysis.
    Neurology. 2025;105:e214033.
    

    >> Share

    
    

    
    Neuropsychology

16. BARVAS E, Mattavelli G, Guttmann S, Papagno C, et al
    Using the Modified Taylor Complex Figure-Recognition Trial (MTCF-RT) to differentiate amnestic patients with Alzheimer's disease from patients with memory deficits due to Parkinson's disease or subcortical ischemic vascular dementia.
    Neuropsychology. 2025 Aug 25. doi: 10.1037/neu0001036.
    

    >> Share

    
    

    
    Neuroscience

17. ATANASOVSKI D, Bergquist F, Eriksson E, Carlsson T, et al
    The dopamine stabilizer (-)-OSU6162 attenuates levodopa-induced dyskinesia in the unilateral 6-hydroxydopamine rat model of Parkinson's disease.
    Neuroscience. 2025 Aug 23:S0306-4522(25)00889.
    

    >> Share

    
    
18. DA SILVA CHAAR NETA R, da Silva Batista C, Machado Palmerim EM, Costa Dias HM, et al
    The impact of social isolation due to the COVID-19 pandemic on functional performance, fall risk, and gait in individuals with Parkinson's Disease: a systematic review.
    Neuroscience. 2025;584:113-126.
    

    >> Share

    
    
19. GWEDELA MNV, Gadama Y, Phiri TE
    Parkinson's disease in Malawi: A cross-sectional Study of clinical profiles and risk factors.
    Neuroscience. 2025;584:88-92.
    

    >> Share

    
    

    
    PLoS One

20. UMEMURA A, Sato K, Iwamuro H, Uchiyama S, et al
    Effects of transcranial direct current stimulation using a commercially available device on gait in Parkinson's disease with freezing of gait.
    PLoS One. 2025;20:e0330286.
    

    >> Share

    
    
21. LARSSON V, Hall S, Blennow K, Hansson O, et al
    Olfactory dysfunction and amyloid-positivity in Parkinson's disease-longitudinal analysis of cognitive decline and cerebrospinal fluid markers.
    PLoS One. 2025;20:e0325560.
    

    >> Share

    
    
22. PAPIC E, Racki V, Hero M, Zimani AN, et al
    Microbial diversity in drug-naive Parkinson's disease patients.
    PLoS One. 2025;20:e0328761.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share